Concepedia

Publication | Closed Access

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

24

Citations

0

References

2006

Year

George G. Shashaty, Raymond Frankewich, Tamal Chakraborti, Jasti B. Choudary, Suliman Al‐Fayoumi, Alice Kacuba, Sonia Velasco del Castillo, Kathy Robie‐Suh, Dwaine Rieves, K Weiss,
PubMed

Abstract

The FDA granted deferasirox accelerated approval on November 2, 2005, for use in treating chronic iron overload due to transfusional hemosiderosis in patients > or =2 years of age. The sponsor must obtain clinical data demonstrating the drug's long-term safety and effectiveness.